<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552369</url>
  </required_header>
  <id_info>
    <org_study_id>11-0073</org_study_id>
    <nct_id>NCT01552369</nct_id>
  </id_info>
  <brief_title>CMV Antiviral Prevention Strategies in D+R-Liver Transplants (&quot;CAPSIL&quot;)</brief_title>
  <official_title>Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV)
      disease in R-D+ liver transplant patients. Subjects will be randomized within 10 days of
      transplant to receive in an open label design, either antiviral prophylaxis with
      valganciclovir, 900 mg orally once daily or preemptive therapy (weekly monitoring for CMV
      viremia by plasma PCR) for 100 days post-randomization with initiation of oral valganciclovir
      900mg orally twice daily at onset of CMV viremia and continued until plasma PCR is negative
      on two consecutive weekly PCR tests). A minimum of 176 subjects will be enrolled in the
      study. The study duration is 7 years. The primary objective of this study is to compare
      prophylaxis versus preemptive therapy using valganciclovir for the prevention of CMV disease
      in R-/D+ liver transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, multicenter trial of preemptive therapy vs. prophylaxis
      for prevention of Cytomegalovirus (CMV) disease in seronegative recipient- seropositive donor
      (R-D+) liver transplant patients.Subjects will be randomized within 10 days of transplant to
      receive in an open label design, either antiviral prophylaxis with valganciclovir 900 mg
      orally once daily or preemptive therapy for 100 days post-randomization with initiation of
      oral valganciclovir 900mg orally twice daily at onset of CMV viremia (monitored weekly) and
      continued until plasma PCR is negative on two consecutive weekly PCR tests. Study
      participants will be followed during the intervention period (100 days post randomization)
      and until 12 months post-transplant for CMV disease, toxicity, and clinical outcomes
      (opportunistic infections, rejection, graft loss and mortality). Drug safety labs will be
      assessed and recorded for the entire treatment period in both the prophylaxis and preemptive
      group. Re-transplantation and all-cause mortality will also be assessed at study closure and
      no longer than 5 years after enrollment. Additionally, the impact of the two CMV prevention
      strategies on CMV-specific cellular and humoral immune responses will be evaluated at 100
      days after randomization, and 6 and 12 months post-transplant. A minimum of 176 subjects will
      be enrolled in the study. Allowing for over-enrollment to replace dropouts, up to 205
      subjects may be enrolled to achieve the target enrollment of 176. Subjects will be randomized
      into one of the two groups in 1:1 ratio. The study duration is 7 years. The primary objective
      of this study is to compare prophylaxis versus preemptive therapy using valganciclovir for
      the prevention of CMV disease in R-/D+ liver transplant recipients. The secondary objectives
      are:1) to assess the two preventive strategies for clinical outcomes (major bacterial, fungal
      and non-CMV viral infections, rejection, graft loss and mortality) at one year post
      transplantation; 2) to assess the two preventive strategies for hematologic toxicity
      (assessment of neutropenia and receipt of hematopoietic growth factor during study days
      1-107).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2012</start_date>
  <completion_date type="Actual">June 22, 2018</completion_date>
  <primary_completion_date type="Actual">June 22, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Cytomegalovirus (CMV) Disease.</measure>
    <time_frame>365 days post-transplant</time_frame>
    <description>CMV disease as verified by an independent end point committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Survival probability at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Allograft Rejection</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Number of subjects with allograft rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Loss</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Incidence of graft loss (re-transplantation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late-onset CMV Disease</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Incidence of late-onset CMV disease (occurring after 100 days post-randomization) as adjudicated by end point committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacterial Infections</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Incidence of bacterial opportunistic infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Fungal Infections</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Opportunistic fungal infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Non-CMV Viral Infections</measure>
    <time_frame>Up to 365 days post-transplant</time_frame>
    <description>Incidence of non-CMV viral infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutropenia</measure>
    <time_frame>Day 1 through Day 107</time_frame>
    <description>Incidence of neutropenia less than 1000/µL while on valganciclovir treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutropenia Less Than 500</measure>
    <time_frame>prior to day 107</time_frame>
    <description>ANC less than 500 while on valganciclovir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematopoietic Growth Factors</measure>
    <time_frame>Day 1 through Day 107</time_frame>
    <description>Hematopoietic growth factor receipt for ANC less than 500 during valganciclovir treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Cytomegalovirus Infection</condition>
  <arm_group>
    <arm_group_label>Preemptive Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.</description>
    <arm_group_label>Preemptive Therapy</arm_group_label>
    <arm_group_label>Prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be &gt; / = 18 years of age.

          2. Have negative Cytomegalovirus (CMV) serology (confirmed within 6 months of transplant)
             and receive a liver from a donor with positive CMV serology (R-/D+).

          3. Have received their first orthotopic liver transplant (the transplanted liver may be
             deceased donor or live donor graft) within 10 days prior.

          4. Have absolute neutrophil count &gt; 1000/µL at randomization.

          5. - If female, and not postmenopausal or surgically sterile, must have negative
             pregnancy test (serum or urine) within 48 hours prior to randomization and must also
             agree to use medically approved method of contraception. Acceptable methods include:
             barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal
             contraceptives, abstinence for 100 days after randomization and 3 months after
             valganciclovir cessation.

             -- If male, and has not had a vasectomy, he must agree to practice barrier method of
             contraception for 100 days after randomization and 3 months after valganciclovir
             cessation.

          6. Subject or legally authorized representative has provided written informed consent.

        Exclusion Criteria:

          1. Currently enrolled in any interventional trial of an investigational therapeutic agent
             unless co-enrollment has been approved by study Principal Investigators (PIs) and the
             DMID prior to enrollment.

          2. Have hypersensitivity to acyclovir, ganciclovir or valganciclovir.

          3. Be breast-feeding mother.

          4. Have known Human immunodeficiency virus (HIV) infection (based on testing performed
             during the transplant evaluation process).

          5. Be undergoing multi organ transplant or have undergone prior organ transplant.

          6. Have expected life expectancy of less than 72 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ronald Reagan University of California Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-8358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Clinic - Transplant Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic, Rochester - Infectious Diseases</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine - Medicine - Infectious Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh - Medicine - Infectious Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington - Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-7110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 22, 2018</verification_date>
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <results_first_submitted>June 13, 2019</results_first_submitted>
  <results_first_submitted_qc>June 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>cytomegalovirus infections</keyword>
  <keyword>ganciclovir</keyword>
  <keyword>liver transplant</keyword>
  <keyword>preemptive therapy</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>valganciclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT01552369/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>538 liver transplant candidates or recipients were screened. 333 were not eligible. 229 did not meet inclusion criteria. 29 met at least 1 exclusion criteria. 75 unable to give, or refused consent. No study procedures were conducted on these 333 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Preemptive Therapy</title>
          <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=100</description>
        </group>
        <group group_id="P2">
          <title>Prophylaxis</title>
          <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=105</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>One Year</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Final Follow up</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not consent to extended follow up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Preemptive Therapy</title>
          <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=100</description>
        </group>
        <group group_id="B2">
          <title>Prophylaxis</title>
          <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=105</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="49.5" upper_limit="62.5"/>
                    <measurement group_id="B2" value="58" lower_limit="51" upper_limit="63"/>
                    <measurement group_id="B3" value="58" lower_limit="50" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline absolute neutrophil count(ANC)</title>
          <description>ANC collected prior to the initiation of intervention</description>
          <units>Count per 1000 cells/µL</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6888" lower_limit="3500" upper_limit="8640"/>
                    <measurement group_id="B2" value="7409" lower_limit="3600" upper_limit="9640"/>
                    <measurement group_id="B3" value="7160" lower_limit="3600" upper_limit="9325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Cytomegalovirus (CMV) Disease.</title>
        <description>CMV disease as verified by an independent end point committee</description>
        <time_frame>365 days post-transplant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cytomegalovirus (CMV) Disease.</title>
          <description>CMV disease as verified by an independent end point committee</description>
          <population>All randomized subjects</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0396</p_value>
            <method>Mantel Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Competing risk regression</method>
            <method_desc>Death was considered a competing risk.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
            <estimate_desc>The risk of CMV disease is 2.2x higher in the prophylaxis group when compared to the preemptive group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>Survival probability at 1 year</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <population>Intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=100</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=105</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>Survival probability at 1 year</description>
          <population>Intent to treat (ITT) population</population>
          <units>survivor probabillity</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".880" lower_limit=".798" upper_limit=".930"/>
                    <measurement group_id="O2" value=".933" lower_limit=".865" upper_limit=".967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>log-rank test for equality of survivor functions</non_inferiority_desc>
            <p_value>0.19</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Allograft Rejection</title>
        <description>Number of subjects with allograft rejection</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Allograft Rejection</title>
          <description>Number of subjects with allograft rejection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>The odds of rejection in prophylaxis group compared to preemptive group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Loss</title>
        <description>Incidence of graft loss (re-transplantation)</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Loss</title>
          <description>Incidence of graft loss (re-transplantation)</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>6.92</ci_upper_limit>
            <estimate_desc>The odds of graft loss in prophylaxis group compared to preemptive group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late-onset CMV Disease</title>
        <description>Incidence of late-onset CMV disease (occurring after 100 days post-randomization) as adjudicated by end point committee</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Late-onset CMV Disease</title>
          <description>Incidence of late-onset CMV disease (occurring after 100 days post-randomization) as adjudicated by end point committee</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>8.69</ci_upper_limit>
            <estimate_desc>Odds of late disease in prophylaxis group compared to preemptive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacterial Infections</title>
        <description>Incidence of bacterial opportunistic infections</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Bacterial Infections</title>
          <description>Incidence of bacterial opportunistic infections</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
            <estimate_desc>Odds of bacterial infection in prophylaxis subjects compared to preemptive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Fungal Infections</title>
        <description>Opportunistic fungal infections</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Fungal Infections</title>
          <description>Opportunistic fungal infections</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>7.62</ci_upper_limit>
            <estimate_desc>Odds of fungal disease in prophylaxis group compared to preemptive</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Non-CMV Viral Infections</title>
        <description>Incidence of non-CMV viral infections</description>
        <time_frame>Up to 365 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Non-CMV Viral Infections</title>
          <description>Incidence of non-CMV viral infections</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutropenia</title>
        <description>Incidence of neutropenia less than 1000/µL while on valganciclovir treatment</description>
        <time_frame>Day 1 through Day 107</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutropenia</title>
          <description>Incidence of neutropenia less than 1000/µL while on valganciclovir treatment</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutropenia Less Than 500</title>
        <description>ANC less than 500 while on valganciclovir</description>
        <time_frame>prior to day 107</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutropenia Less Than 500</title>
          <description>ANC less than 500 while on valganciclovir</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hematopoietic Growth Factors</title>
        <description>Hematopoietic growth factor receipt for ANC less than 500 during valganciclovir treatment.</description>
        <time_frame>Day 1 through Day 107</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Preemptive Therapy</title>
            <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis</title>
            <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
          </group>
        </group_list>
        <measure>
          <title>Hematopoietic Growth Factors</title>
          <description>Hematopoietic growth factor receipt for ANC less than 500 during valganciclovir treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Liver transplant recipients represent a population in whom a high rate of medical events are commonly seen during the post-transplant course. For this study, adverse events were:
Any clinically important untoward medical occurrence in a subject receiving study drug that is different from what is expected in the clinical course of a patient with a liver transplant.
Any clinically important, untoward medical occurrence thought to be related to the study drug, regardless of 'expectedness'.</desc>
      <group_list>
        <group group_id="E1">
          <title>Preemptive Therapy</title>
          <description>900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction.</description>
        </group>
        <group group_id="E2">
          <title>Prophylaxis</title>
          <description>900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nina Singh, MD</name_or_title>
      <organization>University of Pittsburgh - Medicine - Infectious Diseases</organization>
      <phone>412-360-1688</phone>
      <email>nis5@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

